M
Mignon L. Loh
Researcher at University of California, San Francisco
Publications - 472
Citations - 42124
Mignon L. Loh is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Leukemia & Medicine. The author has an hindex of 82, co-authored 407 publications receiving 35918 citations. Previous affiliations of Mignon L. Loh include Children's Oncology Group & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children’s Oncology Group (COG) trials.
Kelly W. Maloney,Anne L. Angiolillo,Reuven J. Schore,Meenakshi Devidas,Xiaomin Lu,Cindy Wang,Alison M. Friedmann,Leonard A. Mattano,Mignon L. Loh,Elizabeth A. Raetz,Linda C. Stork,Naomi J. Winick,Stephen P. Hunger,William L. Carroll +13 more
TL;DR: A comparison of grade 3/4 toxicities resulting from delayed intensification of PEG IM in induction and Delayed intensification with AALL0932 shows no difference in toxicity levels between the two doses.
Journal ArticleDOI
FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study
Patrick A. Brown,John A. Kairalla,Joanne M. Hilden,ZoAnn E. Dreyer,Andrew J. Carroll,Nyla A. Heerema,Cindy Wang,Meenakshi Devidas,William L. Carroll,Elizabeth A. Raetz,Mignon L. Loh,Stephen P. Hunger,Michael J. Borowitz,Donald Small +13 more
TL;DR: COG AALL0631 was a randomized trial that tested the hypothesis that the addition of the FLT3i lestaurtinib to post-induction chemotherapy would improve outcomes for KMT2A-r ALL.
Journal ArticleDOI
Intensification of Oral Methotrexate Is Not Superior to Standard Methotrexate Dosing during Maintenance in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932
Anne L. Angiolillo,Reuven J. Schore,Meenakshi Devidas,Xiaomin Lu,Karen R. Rabin,Patrick A. Zweidler-McKay,Michael J. Borowitz,Brent L. Wood,Andrew J. Carroll,Nyla A. Heerema,Cindy Wang,Kelly W. Maloney,Naomi J. Winick,William L. Carroll,Elizabeth A. Raetz,Mignon L. Loh,Stephen P. Hunger +16 more
TL;DR: Patients with average risk ALL, which accounts for a third of all children with ALL, have outstanding outcomes with 5-year DFS/OS rates of 95% and 98% with standard oral MTX dosing during maintenance therapy.
Journal ArticleDOI
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia
Wenjian Yang,Seth E. Karol,Keito Hoshitsuki,Shawna Lee,Eric Larsen,Naomi J. Winick,William L. Carroll,Mignon L. Loh,Elizabeth A. Raetz,Stephen P. Hunger,S. Winter,Kimberly P. Dunsmore,Meenakshi Devidas,Mary V. Relling,Jun Yang +14 more
TL;DR: In this article , a genetic association study of 3557 children, adolescents, and young adults receiving ALL therapy, variants in UGT1A1 and PNPLA3 were associated with hyperbilirubinemia and elevated alanine aminotransferase and aspartate aminoton-transferase levels, respectively.
Journal ArticleDOI
SSBP2-CSF1R is a Recurrent Fusion in B-lineage Acute Lymphoblastic Leukaemia with Diverse Genetic Presentation and Variable Outcome
Claire Schwab,Kathryn G. Roberts,Judith M. Boer,Gudrun Göhring,Doris Steinemann,Ajay Vora,Christine Macartney,Rachael Hough,Zoe Thorn,Richard Dillon,Gabriele Escherich,Giovanni Cazzaniga,Brigitte Schlegelberger,Mignon L. Loh,Monique L. den Boer,Anthony V. Moorman,Christine J. Harrison +16 more